Posted by Michael Wonder on 21 Mar 2022
Mum’s fear as promising cancer drug out of reach
21 March 2022 - A terminally ill mum desperate for “more time” with her family was “broken” when she learnt the costly drug wasn’t on the PBS.
Tucatinib was denied a Pharmaceutical Benefits Scheme listing last year after an independent committee found the incremental cost effective ratio — which weighs up the cost of a drug and its benefits against existing treatments — was “unacceptably high”.
